精鼎医药荣获Scrip“更佳合同研究组织”称号

2020-12-07 精鼎医药 精鼎医药

精鼎医药荣获Scrip“最佳合同研究组织”称号

2020年12月7日,精鼎医药,一家领先的、致力于在临床开发到商业化的各个阶段加速创新疗法的研发和上市,以改善人类健康的解决方案提供者,近日获得了第16届年度Scrip奖项颁发的全套服务提供商类“最佳合同研究组织(CRO)”称号。该奖项的颁奖典礼于12月2日在线上举办。

精鼎医药首席执行官Jamie Macdonald表示:“我们十分荣幸被Scrip评为行业最佳CRO,这一奖项的获得主要归功于我们杰出的员工团队,因为他们始终孜孜不倦地为客户提供重要见解,并以改善患者治疗效果为使命。更令人欣慰的是,在全球新冠疫情的情况下,我们的行业正在抓住机会,加速采用真实世界和数据驱动的方式进行临床试验设计,从而更快地为患者带去新疗法。”


Scrip奖项是全球最具影响力的权威行业评选活动之一,由全球制药和生物医学行业智库Informa Pharma Intelligence发起,至今已连续16年举办。它是对制药、生物科技和其他相关行业在改善人类健康方面的贡献的重要表彰,由数名生命科学行业领袖组成的评审团进行评选。精鼎医药不断超越申办方期望,在创新患者招募策略、提高数据质量、加大进度和透明度,以及简化数据收集和报告流程等方面具有卓越的能力和优势,使其在奖项评选中脱颖而出。

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950413, encodeId=3b6e195041304, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 09 16:01:33 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410087, encodeId=4c8e141008e01, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 08 15:01:33 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614868, encodeId=47191614868c5, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Dec 08 15:01:33 CST 2020, time=2020-12-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950413, encodeId=3b6e195041304, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 09 16:01:33 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410087, encodeId=4c8e141008e01, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 08 15:01:33 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614868, encodeId=47191614868c5, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Dec 08 15:01:33 CST 2020, time=2020-12-08, status=1, ipAttribution=)]
    2020-12-08 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950413, encodeId=3b6e195041304, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Jul 09 16:01:33 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410087, encodeId=4c8e141008e01, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 08 15:01:33 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614868, encodeId=47191614868c5, content=<a href='/topic/show?id=af2116063a2' target=_blank style='color:#2F92EE;'>#SCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16063, encryptionId=af2116063a2, topicName=SCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=914b19549580, createdName=12498877m104暂无昵称, createdTime=Tue Dec 08 15:01:33 CST 2020, time=2020-12-08, status=1, ipAttribution=)]